Shanghai BDgene Co., Ltd. is advancing its CRISPR/Cas9 gene editing therapy, BD113vLVP, targeting primary open-angle glaucoma (POAG) with MYOC gene mutations. The therapy addresses a significant unmet medical need in glaucoma management, particularly for patients with elevated intraocular pressure (IOP) resistant to conventional treatments. The global glaucoma therapeutics market is projected to grow, driven by increasing prevalence and advancements in gene therapy. BDgene's innovative approach positions it competitively within the gene therapy landscape, although it faces potential competition from established pharmaceutical companies and emerging biotech firms focusing on ocular diseases. Diligence is warranted regarding regulatory pathways and potential market access challenges, particularly in light of the evolving landscape of gene therapies.